Assessing a drug candidate’s metabolic profile early in the discovery process offers insight into its metabolic clearance pathways in both pre-clinical species and humans. Q² Solutions’ global bioanalytical and ADME laboratory network offers a range of liquid chromatography/ mass spectrometry services to support discovery and development metabolite identification and profiling.

Specific capabilities using high-resolution mass spectrometry (HRMS) include:

• Metabolite profiling and identification using liver microsomes or hepatocytes, as well as novel hepatocyte co-culture models for profiling slowly metabolized drug candidates 
• Exploratory profiling using unlabeled drug in preclinical and human clinical samples
• Radio-profiling of both preclinical and human clinical samples
• Reactive intermediate screens evaluating glutathione/cyanide trapping drug candidates (microsomes)